Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response

Journal of Clinical Investigation

Volumn 125, Issue 5, 2015, Pages 1827-1838

  Adekambi, Toidi ^a   Ibegbu, Chris C ^a   Cagle, Stephanie ^a   Kalokhe, Ameeta S ^a   Wang, Yun F ^a,b   Hu, Yijuan ^c   Day, Cheryl L ^a   Ray, Susan M ^a   Rengarajan, Jyothi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GRADY MEMORIAL HOSPITAL   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD38 ANTIGEN; CD4 ANTIGEN; ETHAMBUTOL; GAMMA INTERFERON; HLA DR ANTIGEN; ISONIAZID; KI 67 ANTIGEN; PYRAZINAMIDE; RIFAMPICIN; CD38 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL LOAD; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FLOW CYTOMETRY; GENE EXPRESSION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; TREATMENT RESPONSE; ADOLESCENT; ASYMPTOMATIC DISEASE; BLOOD; CHEMISTRY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG MONITORING; FEMALE; GEORGIA; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; MALE; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; SOUTH AFRICA; SPUTUM; TUBERCULOSIS, PULMONARY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; ANTITUBERCULAR AGENTS; ASYMPTOMATIC DISEASES; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; DIAGNOSIS, DIFFERENTIAL; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; GEORGIA; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; KI-67 ANTIGEN; LATENT TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84929001577     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77990     Document Type: Article

References (50)

1. Parrish NM, Carroll KC. Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings. J Clin Microbiol. 2011;49(3):772-776.
2. Davies PD, Pai M. The diagnosis and misdiagnosis of tuberculosis. Int J Tuberc Lung Dis. 2008;12(11):1226-1234.
3. Nyendak MR, Lewinsohn DA, Lewinsohn DM. New diagnostic methods for tuberculosis. Curr Opin Infect Dis. 2009;22(2):174-182.
4. Thillai M, Pollock K, Pareek M, Lalvani A. Interferon-gamma release assays for tuberculosis: current and future applications. Expert Rev Respir Med. 2014;8(1):67-78.
5. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis. 2005;24(8):529-536.
6. Janssens JP, Roux-Lombard P, Perneger T, Metzger M, Vivien R, Rochat T. Quantitative scoring of an interferon-ã assay for differentiating active from latent tuberculosis. Eur Respir J. 2007;30(4):722-728.
7. Denkinger CM, Pai M, Patel M, Menzies D. γ-Interferon release assay for monitoring of treatment response for active tuberculosis: an explosion in the spaghetti factory. J Clin Microbiol. 2013;51(2):607-610.
8. Rueda CM, Marin ND, Garcia LF, Rojas M. Characterization of CD4 and CD8 T cells producing IFN-γ in human latent and active tuberculosis. Tuberculosis (Edinb). 2010;90(6):346-353.
9. Jones RB, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205(12):2763-2779.
10. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007;8(11):1246-1254.
11. Barry CE, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7(12):845-855.
12. Giorgi JV, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859-870.
13. Hazenberg MD, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17(13):1881-1888.
14. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(2):83-92.
15. Shubinsky G, Schlesinger M. The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. Immunity. 1997;7(3):315-324.
16. Marsh SG, et al. Nomenclature for factors of the HLA system, 2004. Int J Immunogenet. 2005;32(2):107-159.
17. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-322.
18. + T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis. PLoS One. 2012;7(4):e36046.
19. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561-577.
20. Vigano A, Saresella M, Rusconi S, Ferrante P, Clerici M. Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy. Lancet. 1998;352(9144):1905-1906.
21. World Health Organization. Treatment Of Tuberculosis: Guidelines For National Programmes. 4th ed. Geneva, Switzerland: World Health Organization Document; 2010.
22. Day CL, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol. 2011;187(5):2222-2232.
23. Nyendak MR, et al. Mycobacterium tuberculosis specific CD8(+) T cells rapidly decline with antituberculosis treatment. PLoS One. 2013;8(12):e81564.
24. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-γ, yet succumb to tuberculosis. J Immunol. 1999;162(9):5407-5416.
25. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb). 2004;84(1):93-101.
26. Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 2005;26(12):660-667.
27. Sologuren I, et al. Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet. 2011;20(8):1509-1523.
28. + T cell responses discriminate between latent infection and active disease. Nat Med. 2011;17(3):372-376.
29. Sester U, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS One. 2011;6(3):e17813.
30. Rodrigues DS, Medeiros EA, Weckx LY, Bonnez W, Salomao R, Kallas EG. Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin Exp Immunol. 2002;128(1):149-154.
31. Rozot V, et al. Mycobacterium tuberculosis-specific CD8 T cells are functionally and phenotypically different between latent infection and active disease. Eur J Immunol. 2013;43(6):1568-1577.
32. Caccamo N, et al. Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS One. 2009;4(5):e5528.
33. + T cells in HIV-infected individuals with latent tuberculosis. J Infect Dis. 2015;211(4):635-640.
34. + T cells provide an immunologic signature of tuberculosis in young children. Am J Respir Crit Care Med. 2012;185(2):206-212.
35. + cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol. 1993;150(7):3070-3079.
36. + T cell responses during acute HIV-1 infection. J Immunol. 2012;188(5):2198-2206.
37. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177-184.
38. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-γ release assays for detecting active TB: a meta-analysis. Chest. 2010;137(4):952-968.
39. Sester M, et al. Interferon-ã release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011;37(1):100-111.
40. Wallis RS, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2009;9(3):162-172.
41. Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010;466(7309):973-977.
42. Bloom CI, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One. 2013;8(8):e70630.
43. Rozot V, et al. Combined use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin Infect Dis. 2015;60(3):432-437.
44. + T cells correlates with persistent active tuberculosis. J Clin Immunol. 2010;30(4):566-573.
45. Streitz M, et al. Loss of receptor on tuberculin-reactive T-cells marks active pulmonary tuberculosis. PLoS One. 2007;2(8):e735.
46. Portevin D, et al. Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. Lancet Infect Dis. 2014;14(10):931-938.
47. Fuhrmann S, Streitz M, Kern F. How flow cytometry is changing the study of TB immunology and clinical diagnosis. Cytometry A. 2008;73(11):1100-1106.
48. Riou C, et al. A subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversion. PLoS One. 2014;9(7):e102178.
49. Johnson JL, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558-563.
50. Blumberg HM, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-662.